Medical Condition

osteosarcoma

Total Trials

10

Recruiting Now

10

Trial Phases

Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for osteosarcoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — osteosarcoma Clinical Trials

How many clinical trials are currently recruiting for osteosarcoma?

ClinicalMetric currently tracks 10 actively recruiting clinical trials for osteosarcoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 10. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for osteosarcoma?

osteosarcoma research spans Phase 1 (2 trials), Phase 2 (5 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a osteosarcoma clinical trial?

Eligibility criteria for osteosarcoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

Instituto do Cancer do Estado de São Paulo 1 trial

University of Wisconsin, Madison 1 trial

Hansoh BioMedical R&D Company 1 trial

University of Florida 1 trial

Sun Yat-sen University 1 trial

Recruiting Clinical Trials

NCT06638931 Phase 2

Recruiting

Agnostic Therapy in Rare Solid Tumors

Instituto do Cancer do Estado ...

View Trial →

NCT02508038 Phase 1

Recruiting

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

University of Wisconsin, Madis...

View Trial →

NCT05830123 Phase 2

Recruiting

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

Hansoh BioMedical R&D Company

View Trial →

NCT00411060

Recruiting

Clinical Orthopaedic Data Bank (Acute and Chronic)

University of Florida

View Trial →

NCT07602049 Phase 2

Recruiting

Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma

Sun Yat-sen University

View Trial →

NCT06492954 Phase 1

Recruiting

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

Peking University People's Hos...

View Trial →

NCT07129226

Recruiting

Musculoskeletal Cancers Remote Monitoring and Care

Case Comprehensive Cancer Cent...

View Trial →

NCT04055220

Recruiting

Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma

Related Conditions

angiosarcoma (2) neuroblastoma (2) leiomyosarcoma (2) primitive neuroectodermal tumor (2) ewing sarcoma (2) urachal cancer (1) parathyroid carcinoma (1) fibrolamellar carcinoma (1) secretory carcinoma of breast (1) anal neoplasms (1) metaplastic breast carcinoma (1) translocation renal cell carcinoma (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology